<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Fri, 26 Dec 2025 07:00:25 +0000</lastBuildDate>
    <item>
      <title>#1 [90/100] Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41448222/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41448222/</guid>
      <dc:creator>Bourhis J, Aup√©rin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, Sun XS, Saada E, Cirauqui B, Rutkowski T, et al.</dc:creator>
      <pubDate>Mon, 22 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üî• CRITICAL - Score: 90/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a randomized, open-label, phase 3 trial published in a top-tier journal (Lancet) evaluating a novel combination therapy for high-risk squamous cell carcinoma of the head and neck, which has the potential to significantly change postoperative treatment paradigms.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Bourhis J, Aup√©rin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, Sun XS, Saada E, Cirauqui B, Rutkowski T, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Lancet (London, England) | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/S0140-6736(25)01850-1'&gt;10.1016/S0140-6736(25)01850-1&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-22&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41448222/'&gt;41448222&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Postoperative cisplatin and radiotherapy is the standard of care for high-risk resected locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). The NIVOPOST-OP trial aimed to assess the efficacy and safety of programmed death 1 blockade by nivolumab added to cisplatin and radiotherapy in this setting. METHODS: This open-label, phase 3 trial evaluated adding nivolumab to cisplatin and radiotherapy after surgery for LA-SCCHN with high-risk pathological features. The main inclusion criteria were age 19-74 years, an Eastern Cooperative Oncology Group performance status 0-1, squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx resected with macroscopic complete resection, and at least one high-risk pathological feature: nodal extracapsular extension, microscopically positive margins, four or more cervical nodal involvements without extracapsular extension, and multiple perineural invasions. 680 participants recruited in 82 sites across six countries (France, Spain, Poland, Belgium, Greece, and Switzerland) were randomly assigned 1:1 to receive cisplatin and radiotherapy (66 Gy, cisplatin 100 mg/m2 intravenously once every 3 weeks, for three cycles); or nivolumab 240 mg intravenously, followed by cisplatin and radiotherapy with three cycles of concomitant nivolumab 360 mg once every 3 weeks, and six cycles of adjuvant nivolumab 480 mg once every 4 weeks. The primary endpoint was disease-free survival as per investigator assessment in the intention-to-treat population. 230 disease-free survival events (relapses or deaths) were required to detect a hazard ratio of 0¬∑65 with 0¬∑05 two-sided Œ± error, with 90% power. The trial is registered at ClinicalTrials.gov (NCT03576417) and is active, but not recruiting. FINDINGS: The 680 patients were recruited from Oct 15, 2018, to July 3, 2024. The analysis was based on 666 participants randomly assigned until the cutoff date (April 30, 2024), at which point the required number of events was reached (median follow-up 30¬∑3 months). Disease-free survival was significantly improved with nivolumab, cisplatin, and radiotherapy versus cisplatin and radiotherapy alone, irrespective of programmed death ligand 1 expression (HR 0¬∑76; 95% CI 0¬∑60-0¬∑98; stratified log-rank test p value=0¬∑034). There was an increase in the rate of participants with treatment-related grade 4 adverse events with nivolumab, cisplatin, and radiotherapy compared with cisplatin and radiotherapy (30 [10%] of 312 vs 16 [5%] of 306). Treatment-related deaths occurred in two participants in each group. INTERPRETATION: Nivolumab added to cisplatin and radiotherapy in high-risk resected LA-SCCHN improves disease-free survival with moderate toxic effect increase, and can be proposed as a new standard treatment. FUNDING: Groupe Oncologie Radiotherapie Tete Et Cou (GORTEC) and Bristol Myers Squibb.</description>
    </item>
    <item>
      <title>#2 [85/100] De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41449152/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41449152/</guid>
      <dc:creator>Petkar I</dc:creator>
      <pubDate>Thu, 01 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚≠ê HIGH IMPACT - Score: 85/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper discusses the de-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer, which is a significant clinical question with potential practice-changing implications, published in a top-tier journal, The Lancet Oncology.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Petkar I&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; The Lancet. Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/S1470-2045(25)00726-0'&gt;10.1016/S1470-2045(25)00726-0&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-01&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41449152/'&gt;41449152&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#3 [85/100] INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41427951/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41427951/</guid>
      <dc:creator>Rischin D, Hansen AR, Cohen EEW, Tahara M, Harrington KJ, Haddad RI, Licitra L, Mehanna H, Ferris RL, Koralewski P, et al.</dc:creator>
      <pubDate>Mon, 22 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚≠ê HIGH IMPACT - Score: 85/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a randomized Phase II/III study evaluating a novel combination therapy in a significant patient population with recurrent/metastatic head and neck squamous cell carcinoma, which has the potential for practice-changing implications based on its design and endpoints.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Rischin D, Hansen AR, Cohen EEW, Tahara M, Harrington KJ, Haddad RI, Licitra L, Mehanna H, Ferris RL, Koralewski P, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Clinical cancer research : an official journal of the American Association for Cancer Research | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1158/1078-0432.CCR-25-1197'&gt;10.1158/1078-0432.CCR-25-1197&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-22&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41427951/'&gt;41427951&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Feladilimab, an inducible T-cell co‚Äëstimulatory receptor agonist, demonstrated clinical activity in combination with pembrolizumab in a Phase I head and neck squamous cell carcinoma (HNSCC) expansion cohort, prompting further evaluation in patients in this setting. PATIENTS AND METHODS: INDUCE-3 (NCT04128696) was a randomized, double-blind, Phase II/III study in first-line programmed death-ligand 1-positive recurrent and/or metastatic HNSCC patients. A 2-in-1 adaptive design was implemented, with an option to expand the Phase II study into a Phase III confirmatory study. Patients were randomized 1:1 to receive feladilimab plus pembrolizumab or placebo plus pembrolizumab; up to 35 cycles of treatment for approximately 2 years. Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS). RESULTS: The study enrolled 315 patients. Following review of unblinded interim data in 140 patients, an Independent Data Monitoring Committee recommended stopping patient accrual based on prespecified criteria. Existing patients discontinued feladilimab or placebo. Pembrolizumab treatment continued until prespecified stopping criteria were met. This study demonstrated no evidence of an effect in favor of feladilimab plus pembrolizumab, with an adjusted HR of 1.51 for OS and 1.40 for PFS (median OS: 44.1 weeks [95% confidence interval (CI): 35.9-NA]; median PFS: 10.1 weeks [95% CI: 9.1-15.0]) versus placebo plus pembrolizumab (median OS: not reached; median PFS: 16.0 weeks [95% CI: 14.3-26.1]). The incidence of treatment-related adverse events was higher in the placebo group. CONCLUSIONS: This analysis does not support the combination of feladilimab plus pembrolizumab due to lack of superiority over placebo plus pembrolizumab.</description>
    </item>
    <item>
      <title>#4 [75/100] International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41449157/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41449157/</guid>
      <dc:creator>Gupta R, Fielder T, Bal M, Chiosea SI, Dahlstrom JE, Kakkar A, Kiss K, Laco J, Mittal N, Pasricha S, et al.</dc:creator>
      <pubDate>Thu, 01 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This paper presents international consensus recommendations for histopathological diagnosis in head and neck squamous cell carcinoma, addressing a critical area of variability in clinical practice, which could influence treatment guidelines and improve patient management.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Gupta R, Fielder T, Bal M, Chiosea SI, Dahlstrom JE, Kakkar A, Kiss K, Laco J, Mittal N, Pasricha S, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; The Lancet. Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/S1470-2045(25)00535-2'&gt;10.1016/S1470-2045(25)00535-2&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-01&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41449157/'&gt;41449157&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Histopathologically detected extranodal extension leads to upstaging and treatment escalation in head and neck squamous cell carcinoma. There is considerable variation in the prevalence of histopathologically detected extranodal extension in comparable studies. The Head and Neck Cancer International Group, which includes 23 organisations managing patients with head and neck cancer, identified several challenges in evaluating histopathologically detected extranodal extension. Thus, the Head and Neck Consensus Language for Ease and Reproducibility (HN-CLEAR) and its global stakeholders prioritised developing diagnostic criteria and uniform terminology for histopathologically detected extranodal extension. The histopathologically detected extranodal extension working group established by WHO, International Collaboration on Cancer Reporting, American Joint Committee on Cancer, Union for International Cancer Control, North American Society of Head and Neck Pathology, and American Academy of Oral and Maxillofacial Pathology committees undertook consensus deliberations using scanned whole slides and a PRISMA literature review-based scoping questionnaire. The guidelines were tested by 30 additional pathologists across six continents and strengthened with prescriptive diagnostic criteria and unifying terminology based on the inter-rater concordance analyses. This Review generates practically useful consensus diagnostic recommendations and aligned terminology for addressing the gaps in the histopathologically detected extranodal extension literature. The recommendations can be used globally and cater to all levels of medical resources, practices, and experiences, thus ensuring equitable patient care.</description>
    </item>
    <item>
      <title>#5 [75/100] NPC-SurvAI: A fully automated deep learning framework for prognostic prediction and risk stratification in patients with nasopharyngeal carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41429722/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41429722/</guid>
      <dc:creator>You J, Ou H, Zhang Y, Wu X, Zhang L, Jin Z, Chen Q, Shen H, Liu X, Sun J, et al.</dc:creator>
      <pubDate>Thu, 01 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study involves a large retrospective analysis of 2180 patients and presents a novel deep learning framework for prognostic prediction in nasopharyngeal carcinoma, which could have significant clinical implications, though it lacks the prospective design and practice-changing findings typical of higher-impact studies.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; You J, Ou H, Zhang Y, Wu X, Zhang L, Jin Z, Chen Q, Shen H, Liu X, Sun J, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2025.111223'&gt;10.1016/j.radonc.2025.111223&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-01&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41429722/'&gt;41429722&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND AND PURPOSE: Deep learning can non-invasively depict the radiological phenotype of tumor. We aimed to propose an end-to-end deep learning framework called NPC-SurvAI to perform prognosis assessment using MRI in nasopharyngeal carcinoma (NPC). METHODS: This retrospective study included 2180 NPC patients who underwent baseline MRI. The NPC-SurvAI comprised an AttVNet for image segmentation and a DenseNet-ICAM for prognosis evaluation, including progression-free survival (PFS) and overall survival (OS). The clinical model was built with age, T-stage, N-stage, and EBV DNA. The image and combined models were developed by the NPC-SurvAI framework. The integrated area under the curve (iAUC) and thetime-dependent AUC (tAUC) were leveraged to measure the predictive accuracy. K-means clustering and Kaplan-Meier survival analysis were utilized to stratify patients into subtypes and compare their prognoses. RESULTS: In the validation cohorts, the AttVNet achieved average Dice similarity coefficients of 0.726-0.764 tumor segmentation. The dynamic change curves of the AUCs over time suggested that the combined model outperformed both the clinical and image models in predicting PFS (iAUC: 0.838-0.884 vs 0.788-0.844 vs 0.738-0.798) and OS (iAUC: 0.842-0.894 vs 0.793-0.853 vs 0.754-0.807) at any time point from 1 to 8‚ÄØyears. Specially, the combined model achieved time-AUCs of 0.844-0.930 for 3-year PFS and 0.827-0.896 for 5-year PFS; 0.838-0.978 for 3-year OS and 0.788-0.871 for 5-year OS. Additionally, patients could be stratified into two subtypes with different survivals (all P‚ÄØ&lt;‚ÄØ0.05). CONCLUSIONS: NPC-SurvAI has the potential to automatically stratify patients with diverse prognoses, which helps clinicians in optimizing treatment decisions and surveillance.</description>
    </item>
    <item>
      <title>#6 [75/100] Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41435207/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41435207/</guid>
      <dc:creator>Ye Z, Mojahed-Yazdi R, Zapaishchykova A, Tak D, Mahootiha M, Pardo JCC, Zielke J, Zha Y, Guthier C, Tishler RB, et al.</dc:creator>
      <pubDate>Tue, 23 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study involves a large retrospective analysis (n=1,733) utilizing advanced AI technology to improve risk stratification in oropharyngeal carcinoma, which has important clinical implications for treatment planning.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ye Z, Mojahed-Yazdi R, Zapaishchykova A, Tak D, Mahootiha M, Pardo JCC, Zielke J, Zha Y, Guthier C, Tishler RB, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Journal of clinical oncology : official journal of the American Society of Clinical Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1200/JCO-24-02679'&gt;10.1200/JCO-24-02679&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-23&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41435207/'&gt;41435207&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Extranodal extension (ENE) is a biomarker in oropharyngeal carcinoma (OPC) but can only be diagnosed via surgical pathology. We applied an automated artificial intelligence (AI) imaging platform integrating lymph node autosegmentation with ENE prediction to determine the prognostic value of the number of predicted ENE nodes. MATERIALS AND METHODS: We conducted a multisite, retrospective study of 1,733 OPC patients with pretreatment computed tomography who underwent definitive radiation therapy across three institutions. Malignant lymph nodes were segmented using a validated deep learning auto-segmentation model, and segmented lymph nodes were sequentially processed with a validated ENE prediction model to calculate number of nodes with AI-predicted ENE (AI-ENE) per patient. We evaluated associations of AI-ENE with disease outcomes using site-stratified, multivariable Cox regression, adjusting for human papillomavirus (HPV) status, smoking pack-years, tumor and nodal stage, age, and sex. We evaluated risk-stratification improvement when incorporating AI-ENE into the Radiation Therapy Oncology Group (RTOG)-0129 risk groupings and derived American Joint Committee on Cancer (AJCC) 8th edition staging with Uno C-indices and decision curve analyses. RESULTS: Overall, median AI-ENE node number was 1 (range, 0-6). AI-ENE node number was independently associated with poorer distant control (DC; hazard ratio [HR], 1.44 [95% CI, 1.23 to 1.69]; P &lt; .001) and overall survival (OS; HR, 1.30 [95% CI, 1.16 to 1.46]; P &lt; .001). Increasing AI-ENE node number was incrementally associated with worse outcome, particularly DC (P &lt; .001). C-indices improved in the external data set when incorporating AI-ENE into RTOG-0129 groupings (OS: 0.70 v 0.65; DC: 0.65 v 0.57) and AJCC-8 stage (OS: 0.75 v 0.70; DC: 0.72 v 0.67; P &lt; .001 for each). The largest improvements were observed among HPV-negative patients (C-index: +15% for OS, +14% for DC). CONCLUSION: Automated, AI-ENE node number is a novel risk factor for OPC that may better inform pretreatment risk stratification and decision-making.</description>
    </item>
    <item>
      <title>#7 [75/100] Effects of exercise on head and neck cancer surgery: a systematic review of randomized controlled trials.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41430445/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41430445/</guid>
      <dc:creator>Ekici E, Y√ºzba≈üƒ±oƒülu √ú, √ñzkeskin M, √ñzden F</dc:creator>
      <pubDate>Mon, 22 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review of randomized controlled trials addresses an important aspect of postoperative care in head and neck cancer patients, potentially influencing quality of life outcomes, although it does not present new primary data or practice-changing findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ekici E, Y√ºzba≈üƒ±oƒülu √ú, √ñzkeskin M, √ñzden F&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1007/s00405-025-09905-9'&gt;10.1007/s00405-025-09905-9&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-22&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41430445/'&gt;41430445&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Understanding and optimizing exercise programs for individuals undergoing head and neck cancer (HNC) surgery is essential for improving postoperative quality of life. This review aims to examine the effects of exercise and physiotherapy interventions on various outcomes in individuals who have undergone HNC surgery. METHODS: PubMed, Web of Science, and Scopus were systematically searched for randomized controlled trials published within the past decade, yielding 14 studies that met the inclusion criteria. Methodological quality and risk of bias were assessed using the Physiotherapy Evidence Database (PEDro) scale. RESULTS: Except for one preoperative instruction session, all interventions were implemented postoperatively. The most frequently evaluated outcomes included shoulder, jaw, and swallowing function, as well as postoperative symptoms. Across studies, exercise programs with varying content consistently improved shoulder mobility, swallowing function, and symptom burden. CONCLUSION: Evidence from current studies demonstrates that exercise interventions contribute to improved functional outcomes and reduced symptom burden, supporting their inclusion as a core component of standard care in patients who have undergone head and neck cancer surgery.</description>
    </item>
    <item>
      <title>#8 [75/100] Efficacy and safety of Mepitel film for radiodermatitis: a systematic review and meta-analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41420160/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41420160/</guid>
      <dc:creator>Ren X, Wang H, Liu J, Yuan Y, Wu T, Zhang H, Yang D, Yan Y, Xu Y, Wei F</dc:creator>
      <pubDate>Fri, 19 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis includes a substantial number of studies and patients (2,313), providing important insights into the efficacy and safety of Mepitel film for radiodermatitis, which is clinically relevant for cancer patients undergoing radiotherapy.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ren X, Wang H, Liu J, Yuan Y, Wu T, Zhang H, Yang D, Yan Y, Xu Y, Wei F&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; BMC cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1186/s12885-025-15465-2'&gt;10.1186/s12885-025-15465-2&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-19&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41420160/'&gt;41420160&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To evaluate the effects of Mepitel film on the prevention and treatment of radiodermatitis. METHODS: We conducted a systematic search across multiple databases, including PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, and SinoMed Database, from their inception until August 6, 2024. We identified randomized controlled trials (RCTs) or controlled clinical trials that assessed the effects of Mepitel film on radiodermatitis. The risk of bias was evaluated using the Revised Cochrane Risk-of-Bias tool for randomized trials (RoB2). Traditional meta-analysis was performed using RevMan 5.3 and Stata 14.0 software. RESULTS: A total of 27 studies involving 2,313 cancer patients were included. The pooled analysis indicated that Mepitel significantly reduced the incidence of radiation dermatitis (OR‚Äâ=‚Äâ0.28, 95%CI 0.16 to 0.50, I2‚Äâ=‚Äâ67%, P‚Äâ&lt;‚Äâ0.0001) compared to the control groups. In the subgroup analysis by cancer type, Mepitel reduced the incidence of radiation dermatitis in nasopharyngeal carcinoma (OR‚Äâ=‚Äâ0.25, 95%CI 0.13 to 0.46, I2‚Äâ=‚Äâ0%, P‚Äâ&lt;‚Äâ0.0001), breast cancer (OR‚Äâ=‚Äâ0.42, 95%CI 0.26 to 0.68, I2‚Äâ=‚Äâ24%, P‚Äâ=‚Äâ0.0004), and various malignancies (OR‚Äâ=‚Äâ0.10, 95%CI 0.06 to 0.16, I2‚Äâ=‚Äâ0%, P‚Äâ&lt;‚Äâ0.00001). Mepitel use was also associated with a lower incidence of moderate and severe skin injury in radiotherapy patients (RTOG grade II OR‚Äâ=‚Äâ0.26, 95%CI 0.16 to 0.42, P‚Äâ&lt;‚Äâ0.00001; RTOG grade III OR‚Äâ=‚Äâ0.19, 95%CI 0.12 to 0.30, P‚Äâ&lt;‚Äâ0.00001; RTOG grade IV OR‚Äâ=‚Äâ0.10, 95%CI 0.03 to 0.36, P‚Äâ=‚Äâ0.0005), as well as a reduction in the severity of radiation-induced skin damage (combined RISRAS score, MD= -0.74 95% CI -1.02 to -0.46, I2‚Äâ=‚Äâ95%, P‚Äâ&lt;‚Äâ0.00001; researcher RISRAS score MD= -0.47 95% CI -0.67 to -0.27, I2‚Äâ=‚Äâ90%, P‚Äâ&lt;‚Äâ0.00001; and patient RISRAS score MD= -1.19 95% CI -1.33 to -1.05, I2‚Äâ=‚Äâ39%, P‚Äâ&lt;‚Äâ0.00001). Additionally, patients treated with Mepitel experienced fewer cases of moist desquamation (OR‚Äâ=‚Äâ0.46, 95%CI 0.25 to 0.83, I2‚Äâ=‚Äâ58%, P‚Äâ=‚Äâ0.010), and shorter healing times (MD= -4.73, 95%CI -7.16 to -2.30, I2‚Äâ=‚Äâ98%, P‚Äâ=‚Äâ0.0001). CONCLUSION: Mepitel interventions significantly reduced RTOG grades and RISRAS scores, decreased the risk of moist desquamation, and shortened healing times for radiation-induced dermatitis in cancer patients. Further clinical studies are needed to better understand the relationship between Mepitel and radiation dermatitis in this patient population.</description>
    </item>
    <item>
      <title>#9 [70/100] Ambient air pollution and laryngeal cancer: A systematic review.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41442908/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41442908/</guid>
      <dc:creator>Soopramanien J, Mittal S, Jadeja K, Soni L, Saghir S, Mannan F</dc:creator>
      <pubDate>Tue, 23 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review includes a large number of participants (over 7.4 million) and addresses an important epidemiological question regarding the association between air pollution and laryngeal cancer, which has potential clinical implications, although it is not a primary research study.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Soopramanien J, Mittal S, Jadeja K, Soni L, Saghir S, Mannan F&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Cancer epidemiology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.canep.2025.102981'&gt;10.1016/j.canep.2025.102981&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-23&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41442908/'&gt;41442908&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;Ambient air pollution is a major global health concern, yet its association with laryngeal cancer remains poorly defined. This systematic review aimed to evaluate the relationship between long-term exposure to outdoor air pollutants and incidence of laryngeal cancer. Comprehensive searches of MEDLINE, EMBASE, CENTRAL, and SCOPUS were conducted from inception to 01/06/2024. Eligible studies included observational and ecological designs reporting quantitative associations between ambient pollutants and laryngeal cancer incidence. Study quality, risk of bias, and evidence certainty graded were appraised using the NIH tool, National Toxicology Program framework and GRADE approach respectively. A total of nine studies (4 ecological, 5 cohort) comprising over 7.4 million participants were included. Each pollutant was analysed by a maximum of 3 studies. Nitrogen dioxide (NO‚ÇÇ) demonstrated the most consistent association with laryngeal cancer, with hazard ratios between 1.18 and 1.24 per 10‚ÄØŒºg/m¬≥‚ÄØincrease. One large cohort reported a significant relationship between particulate matter ‚â§‚ÄØ2.5 Œºm (PM‚ÇÇ.‚ÇÖ) and laryngeal cancer (HR 1.85; 95‚ÄØ% CI: 1.2-2.85), while findings across other pollutants, including PM‚ÇÅ‚ÇÄ, SO‚ÇÇ, O‚ÇÉ, CO, and NO‚Çì, were inconsistent. Although data remain limited, emerging evidence suggests that chronic exposure to ambient NO‚ÇÇ and PM‚ÇÇ.‚ÇÖ may increase laryngeal cancer risk. Future large-scale prospective cohort studies with standardized exposure metrics and robust confounding control are needed to better characterise this relationship. Natural experiments in regions undergoing major air-quality policy changes can provide valuable evidence on the impact of reducing exposure on laryngeal cancer incidence at a population level.</description>
    </item>
    <item>
      <title>#10 [70/100] The actual performance of ML/AI models in predicting radiation-induced toxicity in head and neck cancer: a systematic review and meta-analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41421773/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41421773/</guid>
      <dc:creator>Ugwu GC, Jalali F, Liu G, Li G, Langendijk JA, Alizadeh BZ</dc:creator>
      <pubDate>Thu, 18 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis evaluates the predictive accuracy of AI/ML models for radiation-induced toxicities in head and neck cancer, providing important insights into a relevant clinical issue, though it does not present primary data or a large prospective study.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ugwu GC, Jalali F, Liu G, Li G, Langendijk JA, Alizadeh BZ&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2025.111350'&gt;10.1016/j.radonc.2025.111350&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-18&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41421773/'&gt;41421773&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;An increasing number of Artificial intelligence (AI) and machine learning (ML) models are being developed to predict radiation-induced toxicities (RITs) in patients with head and neck cancer (HNC). But their performance and reliability remain uncertain. This systematic review and meta-analysis evaluated the predictive accuracy and methodological quality of these models. We comprehensively searched PubMed, EMBASE, Web of Science, and the Cochrane Library to identify studies reporting on ML/AI models for predicting RITs in HNC patients. Eligible studies were assessed for bias risk using the PROBAST tool, and key performance metrics, including the area under the receiver operating curve (AUROC), were extracted. A hierarchical multilevel meta-analysis was performed to estimate pooled AUC values, and subgroup analyses explored the influence of study characteristics on model performance. A total of 67 studies with a total of 568 models were included, showing moderate discriminatory power of ML/AI models, with a pooled AUC = 0.76; 95‚ÄØ% CI: 0.73-0.78. Nonetheless, substantial heterogeneity was observed across studies. Incorporating imaging biomarkers significantly improved model performance. Prospective and internal validation showed comparable performance; external validation shows true generalizability. The predominance of retrospective designs and variability in predictor selection may have introduced bias, affecting model reliability and generalisability. ML/AI models hold promise for predicting RITs in HNC patients, but methodological constraints limit their applicability. Standardised and transparent reporting of model development and validation processes is vital for improving comparability among studies. Future research should explore hybrid modelling methods and the integration of clinical, dosimetric, radiomic, and genomic data to boost predictive accuracy.</description>
    </item>
  </channel>
</rss>
